Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 2/20 | 0.54 |
| ▸ | CDC7 | O00311 | 5/20 | 0.53 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.53 |
| ▸ | CLK1 | P49759 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.53 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.53 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.53 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 2/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.34 |
| ▸ | GCGR | P47871 | 1/20 | 0.34 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.34 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL385827 | 0.92 | PIM1 (0.57) | PIM1CDC7CSNK2A2CLK1GSK3B | |
| SCHEMBL385748 | 0.88 | PIM1 (0.67) | PIM1CDC7CSNK2A2CLK1GSK3B | |
| SCHEMBL385553 | 0.88 | CDC7 (0.66) | PIM1CDC7CSNK2A2CLK1GSK3B | |
| Hydrochloric Acid SCHEMBL386384 | 0.87 | PIM1 (0.66) | PIM1CDC7CSNK2A2CLK1GSK3B | |
| SCHEMBL383300 | 0.84 | CDC7 (0.64) | PIM1CDC7CSNK2A2CLK1GSK3B | |
| SCHEMBL385492 | 0.84 | CDC7 (0.64) | PIM1CDC7CSNK2A2CLK1GSK3B | |
| SCHEMBL385740 | 0.83 | PIM1 (0.66) | PIM1CDC7CSNK2A2CLK1GSK3B | |
| SCHEMBL385518 | 0.80 | PIM1 (0.67) | PIM1CDC7CSNK2A2CLK1GSK3B | |
| SCHEMBL383588 | 0.80 | PIM1 (0.70) | PIM1CDC7CSNK2A2CLK1GSK3B | |
| SCHEMBL383070 | 0.78 | PIM1 (0.67) | PIM1CDC7CSNK2A2CLK1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101625-B2 | Pyrimidinones as Casein Kinase II (CK2) modulators | EXELIXIS, INC. (US) | 2012-01-24 | — | — | US | claimed |
| EP-1948617-B1 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS INC (US) | 2011-07-27 | — | — | EP | claimed |
| US-20090215803-A1 | Pyrimidinones as Casein Kinase II (CK2) Modulators | EXELIXIS, INC. | 2009-08-27 | — | — | US | claimed |
| US-8101625-B2 | Pyrimidinones as Casein Kinase II (CK2) modulators | EXELIXIS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101625-B2 | Pyrimidinones as Casein Kinase II (CK2) modulators | EXELIXIS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101625-B2 | Pyrimidinones as Casein Kinase II (CK2) modulators | EXELIXIS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| EP-1948617-B1 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS INC (US) | 2011-07-27 | — | — | EP | disclosed |
| EP-1948617-B1 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS INC (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20090215803-A1 | Pyrimidinones as Casein Kinase II (CK2) Modulators | EXELIXIS, INC. | 2009-08-27 | — | — | US | disclosed |
| US-20090215803-A1 | Pyrimidinones as Casein Kinase II (CK2) Modulators | EXELIXIS, INC. | 2009-08-27 | — | — | US | disclosed |
| US-20090215803-A1 | Pyrimidinones as Casein Kinase II (CK2) Modulators | EXELIXIS, INC. | 2009-08-27 | — | — | US | disclosed |
| WO-2007048065-A2 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215803-A1 | Pyrimidinones as Casein Kinase II (CK2) Modulators | CSNK2A1, CSNK1A1, CSNK2A2 | PIM1 429/4885CDC7 536/4885CSNK2A2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.